Cargando…

Serum Cholesterol Efflux Capacity in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy

PURPOSE: To investigate serum cholesterol efflux capacity (the ability of the serum to accept cholesterol) and factors that regulate it using nuclear magnetic resonance-quantified measures of lipoprotein particle composition and size and apolipoproteins metrics in patients with age-related macular d...

Descripción completa

Detalles Bibliográficos
Autores principales: Yanagi, Yasuo, Yu, Richard M.C., Ahamed, Waseem, Yu, Marco, Teo, Kelvin Yi Chong, Tan, Anna C.S., Cheng, Ching-Yu, Wong, Tien Yin, Apte, Rajendra S., Cheung, Chui Ming Gemmy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562377/
https://www.ncbi.nlm.nih.gov/pubmed/36278032
http://dx.doi.org/10.1016/j.xops.2022.100142
_version_ 1784808158612422656
author Yanagi, Yasuo
Yu, Richard M.C.
Ahamed, Waseem
Yu, Marco
Teo, Kelvin Yi Chong
Tan, Anna C.S.
Cheng, Ching-Yu
Wong, Tien Yin
Apte, Rajendra S.
Cheung, Chui Ming Gemmy
author_facet Yanagi, Yasuo
Yu, Richard M.C.
Ahamed, Waseem
Yu, Marco
Teo, Kelvin Yi Chong
Tan, Anna C.S.
Cheng, Ching-Yu
Wong, Tien Yin
Apte, Rajendra S.
Cheung, Chui Ming Gemmy
author_sort Yanagi, Yasuo
collection PubMed
description PURPOSE: To investigate serum cholesterol efflux capacity (the ability of the serum to accept cholesterol) and factors that regulate it using nuclear magnetic resonance-quantified measures of lipoprotein particle composition and size and apolipoproteins metrics in patients with age-related macular degeneration (AMD). DESIGN: Case-control study. PARTICIPANTS: Four hundred two serum samples from 80 patients with early AMD (eAMD), and 212 patients with neovascular AMD (nAMD), including 80 with typical nAMD (tAMD) and 132 with polypoidal choroidal vasculopathy (PCV), and 110 age- and gender matched control participants. METHODS: Serum from participants showed cholesterol efflux capacity measured using in vitro cell assays and lipoprotein subfractions measured using nuclear magnetic resonance (Nightingale, Ltd). Associations between cholesterol efflux capacity (measured in percentage) and lipid subfractions were investigated in the patients and control participants. MAIN OUTCOME MEASURES: Cholesterol efflux capacity and lipid subfractions in control, eAMD, and nAMD. Associations between HDL subfractions and cholesterol efflux capacity. RESULTS: Cholesterol efflux capacity was higher in patients with eAMD (68.0 ± 11.3% [mean ± standard deviation]) and nAMD (75.9 ± 27.7%) than in the control participants (56.9 ± 16.7%) after adjusting for age, gender, and use of lipid-lowering drug (P < 0.0001). Nuclear magnetic resonance lipidomics demonstrated that the mean diameter of HDL was larger both in eAMD (9.96 ± 0.27 mm [mean ± standard deviation]) and PCV (9.97 ± 0.23 mm) compared with that of the control participants (9.84 ± 0.24 mm; P = 0.0001 for both). Among the 28 HDL subfractions, most of the small, medium, and large HDLs, but none of the 7 extra large HDLs fractions, were associated moderately with cholesterol efflux capacity in eAMD and PCV (R = 0.149–0.277). CONCLUSIONS: Serum cholesterol efflux capacity was increased in eAMD and PCV, but not tAMD, possibly reflecting differential underlying pathophysiologic features of lipid dysregulation in tAMD and PCV. Further studies should be directed toward investigating the diverse biological activities of HDL in AMD, including macular pigment transport, regulation of inflammation, and local cholesterol transport system.
format Online
Article
Text
id pubmed-9562377
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-95623772022-10-21 Serum Cholesterol Efflux Capacity in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy Yanagi, Yasuo Yu, Richard M.C. Ahamed, Waseem Yu, Marco Teo, Kelvin Yi Chong Tan, Anna C.S. Cheng, Ching-Yu Wong, Tien Yin Apte, Rajendra S. Cheung, Chui Ming Gemmy Ophthalmol Sci Original Article PURPOSE: To investigate serum cholesterol efflux capacity (the ability of the serum to accept cholesterol) and factors that regulate it using nuclear magnetic resonance-quantified measures of lipoprotein particle composition and size and apolipoproteins metrics in patients with age-related macular degeneration (AMD). DESIGN: Case-control study. PARTICIPANTS: Four hundred two serum samples from 80 patients with early AMD (eAMD), and 212 patients with neovascular AMD (nAMD), including 80 with typical nAMD (tAMD) and 132 with polypoidal choroidal vasculopathy (PCV), and 110 age- and gender matched control participants. METHODS: Serum from participants showed cholesterol efflux capacity measured using in vitro cell assays and lipoprotein subfractions measured using nuclear magnetic resonance (Nightingale, Ltd). Associations between cholesterol efflux capacity (measured in percentage) and lipid subfractions were investigated in the patients and control participants. MAIN OUTCOME MEASURES: Cholesterol efflux capacity and lipid subfractions in control, eAMD, and nAMD. Associations between HDL subfractions and cholesterol efflux capacity. RESULTS: Cholesterol efflux capacity was higher in patients with eAMD (68.0 ± 11.3% [mean ± standard deviation]) and nAMD (75.9 ± 27.7%) than in the control participants (56.9 ± 16.7%) after adjusting for age, gender, and use of lipid-lowering drug (P < 0.0001). Nuclear magnetic resonance lipidomics demonstrated that the mean diameter of HDL was larger both in eAMD (9.96 ± 0.27 mm [mean ± standard deviation]) and PCV (9.97 ± 0.23 mm) compared with that of the control participants (9.84 ± 0.24 mm; P = 0.0001 for both). Among the 28 HDL subfractions, most of the small, medium, and large HDLs, but none of the 7 extra large HDLs fractions, were associated moderately with cholesterol efflux capacity in eAMD and PCV (R = 0.149–0.277). CONCLUSIONS: Serum cholesterol efflux capacity was increased in eAMD and PCV, but not tAMD, possibly reflecting differential underlying pathophysiologic features of lipid dysregulation in tAMD and PCV. Further studies should be directed toward investigating the diverse biological activities of HDL in AMD, including macular pigment transport, regulation of inflammation, and local cholesterol transport system. Elsevier 2022-03-16 /pmc/articles/PMC9562377/ /pubmed/36278032 http://dx.doi.org/10.1016/j.xops.2022.100142 Text en © 2022 by the American Academy of Ophthalmology. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Original Article
Yanagi, Yasuo
Yu, Richard M.C.
Ahamed, Waseem
Yu, Marco
Teo, Kelvin Yi Chong
Tan, Anna C.S.
Cheng, Ching-Yu
Wong, Tien Yin
Apte, Rajendra S.
Cheung, Chui Ming Gemmy
Serum Cholesterol Efflux Capacity in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
title Serum Cholesterol Efflux Capacity in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
title_full Serum Cholesterol Efflux Capacity in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
title_fullStr Serum Cholesterol Efflux Capacity in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
title_full_unstemmed Serum Cholesterol Efflux Capacity in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
title_short Serum Cholesterol Efflux Capacity in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
title_sort serum cholesterol efflux capacity in age-related macular degeneration and polypoidal choroidal vasculopathy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562377/
https://www.ncbi.nlm.nih.gov/pubmed/36278032
http://dx.doi.org/10.1016/j.xops.2022.100142
work_keys_str_mv AT yanagiyasuo serumcholesteroleffluxcapacityinagerelatedmaculardegenerationandpolypoidalchoroidalvasculopathy
AT yurichardmc serumcholesteroleffluxcapacityinagerelatedmaculardegenerationandpolypoidalchoroidalvasculopathy
AT ahamedwaseem serumcholesteroleffluxcapacityinagerelatedmaculardegenerationandpolypoidalchoroidalvasculopathy
AT yumarco serumcholesteroleffluxcapacityinagerelatedmaculardegenerationandpolypoidalchoroidalvasculopathy
AT teokelvinyichong serumcholesteroleffluxcapacityinagerelatedmaculardegenerationandpolypoidalchoroidalvasculopathy
AT tanannacs serumcholesteroleffluxcapacityinagerelatedmaculardegenerationandpolypoidalchoroidalvasculopathy
AT chengchingyu serumcholesteroleffluxcapacityinagerelatedmaculardegenerationandpolypoidalchoroidalvasculopathy
AT wongtienyin serumcholesteroleffluxcapacityinagerelatedmaculardegenerationandpolypoidalchoroidalvasculopathy
AT apterajendras serumcholesteroleffluxcapacityinagerelatedmaculardegenerationandpolypoidalchoroidalvasculopathy
AT cheungchuiminggemmy serumcholesteroleffluxcapacityinagerelatedmaculardegenerationandpolypoidalchoroidalvasculopathy